Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 6/2020

01-12-2020 | Magnetic Resonance Imaging | Original Article

Comparison of 18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases

Authors: Cristina Emiko Ueda, Paulo Schiavom Duarte, Luciana Audi de Castroneves, George Barbério Coura-Filho, Heitor Naoki Sado, Marcelo Tatit Sapienza, Ana Oliveira Hoff, Carlos Alberto Buchpiguel

Published in: Nuclear Medicine and Molecular Imaging | Issue 6/2020

Login to get access

Abstract

Purpose

To compare the 18F-NaF PET/CT studies (18F-NaF) with other imaging methods in the detection of skeletal metastases (SM) in patients with medullary thyroid cancer (MTC).

Methods

We retrospectively analyzed 31 patients with MTC who performed 18F-NaF to assess SM. The results of the 18F-NaF were compared with other imaging methods performed for metastasis detection: 99Tc-MDP bone scan (BS), magnetic resonance imaging (MRI), contrast-enhanced CT (CT), and 68Ga-Dotatate and 18F-FDG PET/CT studies. A qualitative analysis comparing the 18F-NaF findings with the ones of the other methods was performed, and the results were classified as superior (>), equal (=), and inferior (<).

Results

Eleven patients had no bone metastases detected on any of the imaging methods used. Twenty patients presented SM depicted on 18F-NaF. Of these 20 patients, 12 performed bone scan (in 9 18F-NaF > BS and in 3 18F-NaF = BS), 1 performed 18F-FDG (18F-NaF > 18F-FDG), 4 performed 68Ga-Dotatate (in 2 18F-NaF > 68Ga-Dotatate and in 2 18F-NaF = 68Ga-Dotatate), 20 performed CT of at least one body segment (in 15 18F-NaF = CT and in 5 18F-NaF > CT), and 16 performed MRI of at least one body segment, and in all of them, the 18F-NaF was equal to the MRI. Beside this, the 18F-NaF detected SM in body segments not routinely scanned in MRI and CT.

Conclusion

In patients with MTC, the 18F-NaF seems to be equal or superior to other imaging modalities in the detection of SM and allows the analysis of the whole skeletal in a single study.
Literature
1.
go back to reference Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, et al. A meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523–31.CrossRef Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, et al. A meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523–31.CrossRef
2.
go back to reference Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252–9.CrossRef Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252–9.CrossRef
3.
go back to reference Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med. 2013;38:e290–6.CrossRef Iagaru A, Young P, Mittra E, Dick DW, Herfkens R, Gambhir SS. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clin Nucl Med. 2013;38:e290–6.CrossRef
4.
go back to reference Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.PubMed
5.
go back to reference Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2016;55:59–67.CrossRef Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2016;55:59–67.CrossRef
6.
go back to reference Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, et al. A prospective study comparing Tc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with F-fluoride PET/CT and F-fluoride PET/MRI for diagnosing bone metastases. J Nucl Med. 2017;58:1778–85.CrossRef Löfgren J, Mortensen J, Rasmussen SH, Madsen C, Loft A, Hansen AE, et al. A prospective study comparing Tc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with F-fluoride PET/CT and F-fluoride PET/MRI for diagnosing bone metastases. J Nucl Med. 2017;58:1778–85.CrossRef
7.
go back to reference Hellwig D, Marienhagen J, Menhart K, Grosse J. Nuclear medicine in Germany. Updated key data and trends from official statistics. Nuklearmedizin. 2017;56:55–68.CrossRef Hellwig D, Marienhagen J, Menhart K, Grosse J. Nuclear medicine in Germany. Updated key data and trends from official statistics. Nuklearmedizin. 2017;56:55–68.CrossRef
8.
go back to reference Páez D, Orellana P, Gutiérrez C, Ramirez R, Mut F, Torres L. Current status of nuclear medicine practice in Latin America and the Caribbean. J Nucl Med. 2015;56:1629–34.CrossRef Páez D, Orellana P, Gutiérrez C, Ramirez R, Mut F, Torres L. Current status of nuclear medicine practice in Latin America and the Caribbean. J Nucl Med. 2015;56:1629–34.CrossRef
9.
go back to reference Van Noorden R. Radioisotopes: the medical testing crisis. Nature. 2013;504:202–4.CrossRef Van Noorden R. Radioisotopes: the medical testing crisis. Nature. 2013;504:202–4.CrossRef
10.
go back to reference Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18:1093–100.CrossRef Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist. 2013;18:1093–100.CrossRef
11.
go back to reference Abe K, Adachi I, Miyakawa S, Tanaka M, Yamaguchi K, Tanaka N, et al. Production of calcitonin, adrenocorticotropic hormone, and beta-melanocyte-stimulating hormone in tumors derived from amine precursor uptake and decarboxylation cells. Cancer Res. 1977;37:4190–4.PubMed Abe K, Adachi I, Miyakawa S, Tanaka M, Yamaguchi K, Tanaka N, et al. Production of calcitonin, adrenocorticotropic hormone, and beta-melanocyte-stimulating hormone in tumors derived from amine precursor uptake and decarboxylation cells. Cancer Res. 1977;37:4190–4.PubMed
12.
go back to reference Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657–62.CrossRef Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657–62.CrossRef
13.
go back to reference Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRef Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRef
14.
go back to reference Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.CrossRef Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.CrossRef
15.
go back to reference Altehoefer C, Ghanem N, Högerle S, Moser E, Langer M. Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol. 2001;40:16–23.CrossRef Altehoefer C, Ghanem N, Högerle S, Moser E, Langer M. Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol. 2001;40:16–23.CrossRef
16.
go back to reference Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41–55.CrossRef Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41–55.CrossRef
17.
go back to reference Treglia G, Giovanella L. F-Fluoride (F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines! Eur J Nucl Med Mol Imaging. 2020;47:527–8.CrossRef Treglia G, Giovanella L. F-Fluoride (F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines! Eur J Nucl Med Mol Imaging. 2020;47:527–8.CrossRef
18.
go back to reference Duarte PS. Letter to the Editor: F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:525–6.CrossRef Duarte PS. Letter to the Editor: F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:525–6.CrossRef
19.
go back to reference Duarte PS, de Castroneves LA, Sado HN, Sapienza MT, de Oliveira Hoff AAF, Buchpiguel CA. Bone and calcified soft tissue metastases of medullary thyroid carcinoma better characterized on F-fluoride PET/CT than on Ga-dotatate PET/CT. Nucl Med Mol Imaging. 2018;52:318–23.CrossRef Duarte PS, de Castroneves LA, Sado HN, Sapienza MT, de Oliveira Hoff AAF, Buchpiguel CA. Bone and calcified soft tissue metastases of medullary thyroid carcinoma better characterized on F-fluoride PET/CT than on Ga-dotatate PET/CT. Nucl Med Mol Imaging. 2018;52:318–23.CrossRef
20.
go back to reference Duarte PS, Marin JFG, Filho GBC, Sapienza MT, Buchpiguel CA. 18F-Fluoride uptake in soft tissue metastases of medullary thyroid carcinoma as a marker of progressive calcification. Clin Nucl Med. 2018;43:848–9.CrossRef Duarte PS, Marin JFG, Filho GBC, Sapienza MT, Buchpiguel CA. 18F-Fluoride uptake in soft tissue metastases of medullary thyroid carcinoma as a marker of progressive calcification. Clin Nucl Med. 2018;43:848–9.CrossRef
21.
go back to reference do Vale RHB, Marin JFG, Duarte PS, Sapienza MT, Buchpiguel CA. Visualization of lymph nodal and hepatic metastases of medullary thyroid carcinoma on 18F-fluoride PET/CT. Clin Nucl Med. 2015;40:895–6.CrossRef do Vale RHB, Marin JFG, Duarte PS, Sapienza MT, Buchpiguel CA. Visualization of lymph nodal and hepatic metastases of medullary thyroid carcinoma on 18F-fluoride PET/CT. Clin Nucl Med. 2015;40:895–6.CrossRef
22.
go back to reference Ueda CE, Duarte PS, de Castroneves LA, Flávio J, Marin G, Sado HN, et al. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer. Nucl Med Commun. 2020;41:469–76.CrossRef Ueda CE, Duarte PS, de Castroneves LA, Flávio J, Marin G, Sado HN, et al. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer. Nucl Med Commun. 2020;41:469–76.CrossRef
23.
go back to reference Choksi P, Papaleontiou M, Guo C, Worden F, Banerjee M, Haymart M. Skeletal complications and mortality in thyroid cancer: a population-based study. J Clin Endocrinol Metab. 2017;102:1254–60.CrossRef Choksi P, Papaleontiou M, Guo C, Worden F, Banerjee M, Haymart M. Skeletal complications and mortality in thyroid cancer: a population-based study. J Clin Endocrinol Metab. 2017;102:1254–60.CrossRef
24.
go back to reference Vogel T, Wendler J, Frank-Raue K, Kreissl MC, Spitzweg C, Fassnacht M, et al. Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology. J Clin Endocrinol Metab. 2020;105:2239–46.CrossRef Vogel T, Wendler J, Frank-Raue K, Kreissl MC, Spitzweg C, Fassnacht M, et al. Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology. J Clin Endocrinol Metab. 2020;105:2239–46.CrossRef
25.
go back to reference Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, et al. Bone metastases and skeletal-related events in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2016;101:4871–7.CrossRef Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, et al. Bone metastases and skeletal-related events in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2016;101:4871–7.CrossRef
26.
go back to reference Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61–77.CrossRef Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:61–77.CrossRef
27.
go back to reference Castroneves LA, Coura Filho G, de Freitas RMC, Salles R, Moyses RA, Lopez RVM, et al. Comparison of 68Ga PET/CT to other imaging studies in medullary thyroid cancer: superiority in detecting bone metastases. J Clin Endocrinol Metab. 2018;103:3250–9.CrossRef Castroneves LA, Coura Filho G, de Freitas RMC, Salles R, Moyses RA, Lopez RVM, et al. Comparison of 68Ga PET/CT to other imaging studies in medullary thyroid cancer: superiority in detecting bone metastases. J Clin Endocrinol Metab. 2018;103:3250–9.CrossRef
28.
go back to reference Ota N, Kato K, Iwano S, Ito S, Abe S, Fujita N, et al. Comparison of 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol. 2014;87:20130444.CrossRef Ota N, Kato K, Iwano S, Ito S, Abe S, Fujita N, et al. Comparison of 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol. 2014;87:20130444.CrossRef
29.
go back to reference Lee S-W, Shim SR, Jeong SY, Kim S-J. Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. Clin Nucl Med. 2020;45:341–8.CrossRef Lee S-W, Shim SR, Jeong SY, Kim S-J. Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. Clin Nucl Med. 2020;45:341–8.CrossRef
30.
go back to reference Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010;7:400–9.CrossRef Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010;7:400–9.CrossRef
31.
go back to reference Haubold-Reuter B, Duewell S, Schilcher B, Marincek B, von Schulthess GK. Fast spin echo MRI and bone scintigraphy in the detection of skeletal metastases. Eur Radiol. 1993;3:316–20.CrossRef Haubold-Reuter B, Duewell S, Schilcher B, Marincek B, von Schulthess GK. Fast spin echo MRI and bone scintigraphy in the detection of skeletal metastases. Eur Radiol. 1993;3:316–20.CrossRef
32.
go back to reference Frank JA, Ling A, Patronas NJ, Carrasquillo JA, Horvath K, Hickey AM, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol. 1990;155:1043–8.CrossRef Frank JA, Ling A, Patronas NJ, Carrasquillo JA, Horvath K, Hickey AM, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol. 1990;155:1043–8.CrossRef
33.
go back to reference Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skelet Radiol. 2019;48:1915–24.CrossRef Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skelet Radiol. 2019;48:1915–24.CrossRef
Metadata
Title
Comparison of 18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases
Authors
Cristina Emiko Ueda
Paulo Schiavom Duarte
Luciana Audi de Castroneves
George Barbério Coura-Filho
Heitor Naoki Sado
Marcelo Tatit Sapienza
Ana Oliveira Hoff
Carlos Alberto Buchpiguel
Publication date
01-12-2020
Publisher
Springer Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 6/2020
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-020-00666-3

Other articles of this Issue 6/2020

Nuclear Medicine and Molecular Imaging 6/2020 Go to the issue